Jeff Luber is the CEO of Clairity. As a veteran life sciences and award-winning CEO, Jeff has served as CEO of multiple healthcare companies across oncology, genetic sequencing, infectious disease and digital health. Prior to joining Clairity, Jeff served as CEO of binx health where he led the company from proof-of-concept through FDA clearance and rapid commercialization of the first ever point-of-care molecular platform of its kind for infectious disease testing and he continues to serve as the company’s Chairman. Prior to binx, Jeff served as CEO of Good Start Genetics, the first company to bring next generation sequencing to reproductive health. Under Jeff’s leadership, testing volumes grew by double digits, revenues climbed to the highest mark in the company’s history, culminating in the successful sale of the company in August 2017.

Jeff has served on numerous boards of directors of both public and private companies and earned his Juris Doctor and MBA from Suffolk University. He is also the winner of the 2022 EY Entrepreneur of the Year Award and currently serves as a judge for the annual competition.